TIDMSLN

RNS Number : 2870F

Silence Therapeutics PLC

15 July 2021

Silence Therapeutics Notice of Half Year Results

15 July 2021

LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN (" Silence " or " the Company "), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will release its financial and business results for the half year ended June 30, 2021 on Thursday, August 12, 2021.

Management will host a conference call at 8:00 a.m. EDT / 13:00 BST that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the Investors section of the Silence website, www.silence-therapeutics.com. The webcast will also be archived on the Company's website.

Details of the webcast and conference call:

Dial-in details:

New York, United States: +1 646 741 3167

United States: 1 877 870 9135

London, United Kingdom: +44 2071 928338

United Kingdom: 08002796619

Passcode: 9869230

   Webcast link:   https://edge.media-server.com/mmc/p/g85x6hug

Enquiries:

 
 Silence Therapeutics plc                                Tel: +1 (646) 637-3208 
  Gem Hopkins, Head of IR and Corporate Communications 
  ir@silence-therapeutics.com 
  Investec Bank plc (Nominated Adviser and                Tel: +44 (0) 20 
   Broker)                                                 7597 5970 
   Daniel Adams/Gary Clarence 
 European PR                                             Tel: +44 (0) 20 
  Consilium Strategic Communications                      3709 5700 
  Mary-Jane Elliott/ Angela Gray / Chris Welsh 
  silencetherapeutics@consilium-comms.com

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD(TM) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORGPUCAMUPGGRC

(END) Dow Jones Newswires

July 15, 2021 02:00 ET (06:00 GMT)

Silence Therapeutics (LSE:SLN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Silence Therapeutics.
Silence Therapeutics (LSE:SLN)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Silence Therapeutics.